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Abstract
Background: TBX3 is a T-box transcription factor repressor that is elevated in metastatic breast cancer and is
believed to promote malignancy of tumor cells, possibly by promoting cell survival and epithelial-mesenchymal
transition.
Methods: The relative expression of TBX3 was assessed in the 21T cell lines which were derived from
an individual patient and represent three distinct stages of breast cancer progression: 21PT, atypical
ductal hyperplasia; 21NT, ductal carcinoma in situ; and 21MT-1, invasive mammary carcinoma. Two
different isoforms of TBX3 (TBX3iso1 and TBX3iso2) were overexpressed to evaluate cell survival/colony
forming ability, growth, and invasion in the ductal carcinoma in situ-like 21NT cell line using an in vitro
Matrigel model of cancer progression. In addition, TBX3 expression was knocked down to evaluate
the effects of downregulating TBX3 on the invasive mammary carcinoma-like 21MT-1 cell line. Finally,
PCR array profiling was used to assess alterations in gene expression due to TBX3 overexpression in
the 21NT cells.
Results: TBX3 is abundant in the invasive 21MT-1 cell line, while being minimally expressed in the non-
invasive 21NT and 21PT cell lines. Overexpression of either TBX3iso1 or TBX3iso2 in 21NT cells resulted in
increased cell survival/colony forming ability, growth vs. apoptosis and invasion in Matrigel. In contrast,
short hairpin RNA-mediated knockdown of TBX3 in the 21MT-1 cells resulted in smaller colonies, with a
more regular, less dispersed (less infiltrative) morphology. Array profiling of the 21NT TBX3 iso1 and iso2
transfectants showed that there are common alterations in expression of several genes involved in signal
transduction, cell cycle control/cell survival, epithelial-mesenchymal transition and invasiveness.
Conclusions: Overall, these results indicate that TBX3 (isoform 1 or 2) expression can promote
progression in a model of early breast cancer by altering cell properties involved in cell survival/colony
formation and invasiveness, as well as key regulatory and EMT/invasiveness-related gene expressions.
Keywords: Breast cancer, Ductal carcinoma in situ, Epithelial-mesenchymal transition, Invasive mammary
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Abbreviations: αHE10F, αMEM with L-glutamine, insulin, epidermal growth factor, hydrocortisone, HEPES,
sodium pyruvate, non-essential amino acid, gentamycin, and 10 % FBS; αMEM, Alpha modification of
Eagle’s medium; ADH, Atypical ductal hyperplasia; AKT1, V-Akt murine thymoma viral oncogene homolog
1; AR, Androgen receptor; BRCA1, Breast cancer 1, early onset; BRCA2, Breast cancer 2, early onset;
BSA, Bovine serum albumin; CDKN2A, Cyclin-dependent kinase inhibitor 2A, encodes p14ARF and p16INK4A;
CST6, Cystatin E/M; DCIS, Ductal carcinoma in situ; DOC, Deoxycholic acid; ECL, Enhanced
chemiluminescence; EDTA, Ethylenediaminetetraacetic acid; EGFR, Epidermal growth factor receptor;
EGTA, Ethylene glycol tetraacetic acid; EMT, Epithelial-mesenchymal transition; EV, Empty vector; FBS, Fetal
bovine serum; FOXA1, Forkhead box protein A1; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
IL-6, Interleukin-6; IMC, Invasive mammary carcinoma; JUN, Jun proto-oncogene; KRT8, Keratin 8, type II;
MAPK8, Mitogen-activated protein kinase 8; MKI67, Marker of proliferation Ki67; MLH1, MutL homolog 1,
colon cancer, nonpolyposis type 2; MMP9, Matrix metallopeptidase 9; NBF, Neutral buffered formalin;
NR3C1, Nuclear receptor subfamily 3, group C, member 1 glucocorticoid receptor; P53, p53 tumor
suppressor protein; PBS, Phosphate-buffered saline; PLAU, Plasminogen activator, urokinase; PRDM2, PR
domain containing 2, with ZNF domain; RB1, Retinoblastoma 1; RIPA, Radioimmunoprecipitation assay;
RPLP0, Acidic Ribosomal Phosphoprotein P0; SDS, Sodium dodecyl sulfate; SERPINE1, Serpin peptidase
inhibitor, clade E, member 1; SFN, Stratifin; shRNA, Short hairpin RNA; SNAI2, Snail family zinc finger 2;
SRC, SRC proto-oncogene; TBX3, T-box 3, with two isoforms: TBX3iso1 and TBX3iso2 (also known as TBX3
+ 2a); TWIST1, Twist family BHLH transcription factor 1
Background
Arguably the most critical stage of early breast cancer
progression is the transition from in situ (ductal carcin-
oma in situ, DCIS) to invasive (invasive mammary car-
cinoma, IMC) disease. Although a number of molecular
changes have been identified that accompany invasive
breast cancer [1–6], those that can directly control the
transition from DCIS to IMC remain elusive.
Using microarray analysis, we previously identified T-
box transcription factor 3 (TBX3) as a potential regulator
of progression from DCIS to IMC, using the 21T cell lines
which represent distinct stages of breast cancer progres-
sion [7]. Specifically, we found that invasive, metastatic
21MT-1 cells expressed higher levels of TBX3 than non-
invasive, DCIS-like 21NT cells or non-invasive, atypical
ductal hyperplasia (ADH)-like 21PT cells [7]. TBX3 is a
member of the T-box family of transcription factors that
play an important role in development of many animal
species. In mouse embryo development, a model has
emerged in which TBX3 expression is both induced and
maintained in early mammary gland initiation by Wnt and
fibroblast growth factor (FGF) [8]. In humans, Ulnar-
mammary syndrome, a congenital autosomal dominant
disorder, is caused by mutations that result in haploinsuffi-
ciency of TBX3 and is characterized by upper-limb anom-
alies and mammary gland hypoplasia [9].
TBX3 has been linked to tumorigenesis and is involved
in cell cycle control and inhibition of cell senescence,
through both p53-dependent and independent pathways
[10, 11]. The p53-dependent pathway signals through
p14ARF, a tumor suppressor and cell cycle control protein
that is a product of the cyclin-dependent kinase inhibitor
2A (CDKN2A) gene, along with p16INK4A. TBX3 directly
represses transcription of p14ARF [10, 12]. Downregulation
or inhibition of p14ARF leads to increased proliferation
and immortalization, as well as failure of apoptosis [12].
Aside from its role in the cell cycle, TBX3 is a known re-
pressor of E-cadherin expression in melanoma, leading to
enhanced invasiveness [13, 14]. TBX3 expression has also
been found to be associated with cell survival in hepato-
cellular carcinoma, where it is induced by Wnt/β-catenin
signalling [15].
Two different isoforms of TBX3 have been identified,
TBX3iso1 and TBX3iso2. The TBX3iso2 variant has an
extra 20 amino acids, encoded by exon 2a, inserted into the
T-box domain [9]. As the 2a insertion is within the T-box
domain, which is required for DNA-binding and protein-
protein interactions, it was initially proposed that this vari-
ant may have altered DNA-binding properties, and that it
may in fact interfere with the senescence-inhibiting proper-
ties of the other isoform [16]. However, it has been found
that TBX3iso2 (also referred to as TBX3 + 2a because of
the presence of exon 2a) can indeed bind the DNA-binding
site and act as an anti-senescence factor [17].
Here we examined whether either or both isoforms of
TBX3 could influence breast cancer progression, in par-
ticular the transition from non-invasive to invasive dis-
ease. We show that both isoforms of TBX3 have a
similar functional effect in promoting breast cancer pro-
gression to a more malignant phenotype, and identify
TBX3-induced changes in expression of genes involved
in signal transduction, cell cycle control/cell survival and
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epithelial-mesenchymal transition (EMT)/invasiveness
that may play a role in this progression.
Methods
Cell lines and culture conditions
The 21T parental cell lines (21PT, 21NT, and 21MT-1)
were a kind gift from Dr. Vimla Band (Dana Farber Cancer
Institute, Boston, MA) [18] and were cultured in alpha
modification of Eagle’s medium supplemented with 2.8 μM
hydrocortisone (H), 12.5 ng/ml epidermal growth factor
(E), 2 mM L-glutamine, 1 μg/ml insulin, 10 mM HEPES,
1 mM sodium pyruvate, 0.1 mM non-essential amino acids
and 50 μg/ml gentamycin reagent (called αHE – all supple-
ments from Wisent Bioproducts). For regular culture con-
ditions, the αHE media was further supplemented with
10 % fetal bovine serum (FBS) (Sigma-Aldrich) and named
αHE10F. Stably transfected cells were cultured in αHE10F
containing either 500 μg/ml G418 (Wisent Bioproducts) or
0.8 μg/ml puromycin (Sigma-Aldrich).
Generation of TBX3 expression vectors
Expression vectors were constructed for each TBX3 iso-
form (TBX3iso1and TBX3iso2). To obtain TBX3iso2, PCR
amplification of the whole transcript was performed from a
pOTB7 expression vector containing TBX3iso2 [Gen-
bank:BC025258] (Open Biosystems Thermo Scientific) as
the cDNA template using Phusion High-Fidelity DNA Taq
polymerase (New England BioLabs). Primers used to amp-
lify TBX3iso2 were: forward: 5′-GCC ACC ATG AGC
CTC TCC ATG AGA-3′ and reverse: 5′-TTC GGG ACC
GCC TGC GGG ACC TGT CCG GC-3′. To produce
TBX3iso1, two PCR product fragments, representing the
transcript before (fragment 1) and after (fragment 2) the
66 bp TBX3iso2 addition, were PCR amplified. Primers
used for fragment 1 of TBX3iso1 were: forward: 5′-GCC
ACC ATG AGC CTC TCC ATG AGA-3′ and reverse: 5′-
CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT
GAC-3′. Primers used for fragment 2 of TBX3iso1 were:
forward: 5′-TGG ATT TAC TAT ATT GAA CTC CAT
GCA CAA AT-3′ and reverse: 5′-TTC GGG ACC GCC
TGC GGG ACC TGT CCG GC-3′. All primers used for
generation of the TBX3 expression vectors were purchased
from Sigma-Aldrich. Products were separated on 1 % agar-
ose gel and bands representing TBX3iso2 at ~2000 kb were
extracted and pooled. For TBX3iso1, a band at ~660 kb for
fragment 1 and a band at ~1380 kb for fragment 2 were gel
extracted and pooled. When designing the PCR primers for
the two fragments of TBX3iso1, the reverse primer of the
upstream amplicon (fragment 1) and the forward primer
for the downstream amplicon (fragment 2) had a 20 bp
overlap to ensure that the ends of these amplicons would
anneal in a subsequent PCR reaction to melt the fragments
together. This annealed TBX3iso1 PCR product was puri-
fied and amplified again. After running this PCR product
on a 1 % agarose gel and extracting at ~2000 bp, both
TBX3iso1 and TBX3iso2 PCR products were incubated
with T4 polynucleotide kinase (New England BioLabs), and
purified. Both products were inserted separately into
pZsGreen-C1 plasmids (Clonetech Laboratories), such that
the ZsGreen was fused to the C-terminus of TBX3. To pre-
pare the pZsGreen-C1 plasmid, it was digested with Afe1
(New England BioLabs) and incubated with calf intestinal
alkaline phosphatase (New England BioLabs) to dephos-
phorylate the cut ends. The digested plasmid was electro-
phoresed and gel extracted. The plasmid and TBX3 PCR
products were incubated overnight with ATP and T4 DNA
Ligase (New England BioLabs) at 16 °C to complete
ligation. Competent bacteria (DH5alpha) were transformed
with the ligated plasmid and kanamycin resistant clones
were expanded to isolate DNA. Clones were digested with
the following enzyme pairs to check for proper size and
orientation: AgeI/KpnI, MfeI/XhoI, and NheI/HndIII. Suit-
able clones were sequenced (DNA Sequencing Facility at
Robarts Research Institute, London, ON).
The use of untagged TBX3 was required so the TBX3
expression vectors underwent site directed mutagenesis
in order to introduce a stop codon at the end of full
length TBX3iso1 and TBX3iso2 using QuikChange Site-
Directed Mutagenesis Kit (Agilent Technologies) ac-
cording to the manufacturer’s protocol. Clones were sent
to the DNA Sequencing Facility at Robarts Research In-
stitute for sequencing. Clones with the proper sequence
were used for stable transfections.
Transfections
Purified TBX3iso1 and TBX3iso2 plasmid DNA was trans-
fected using PolyJet DNA In Vitro Transfection Reagent
(SignaGen Laboratories) following the manufacturer’s
protocol. Empty vector (EV) plasmids were transfected as a
control. Stable transfectants were selected in αHE10F con-
taining 500 μg/ml G418 (Wisent Bioproducts). Approxi-
mately two weeks post-transfection, resistant clones were
pooled, expanded, and frozen for later use.
Generation of lentiviral particles and transduction
Generation of short hairpin (sh) RNA containing lentivirus
particles and knockdown of target genes were described
previously [19, 20]. The shRNA target sequence for TBX3
was GCA TAC CAG AAT GAT AAG ATA which targeted
the coding sequence of both TBX3iso1 and TBX3iso2. The
shRNA target sequence for Luciferase (off-target knock-
down control) was ACG CTG AGTACT TCG AAATGT.
The TBX3 shRNA lentivirus particles generated were used
to knockdown TBX3 in the 21MT-1 cell line and Luciferase
shRNA was used a negative control. One week post-
transduction, stable clones were selected in αHE10F con-
taining 0.8 μg/ml puromycin (Sigma-Aldrich) and resistant
clones were pooled, expanded, and frozen for later use.
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Isolation of RNA and quantitative real-time polymerase
chain reaction (qRT-PCR)
Cells were harvested with trypsin and RNA was isolated
using the RNeasy Mini Kit (Qiagen). Samples were treated
with 30U DNase I (Qiagen), and 500 ng of RNA was con-
verted into cDNA with the Superscript III First-Strand Syn-
thesis System (Invitrogen) using Oligo (dT) 12–18 primers
(Invitrogen). qRT-PCR was performed using RT2 SYBR
Green ROX qPCR Mastermix (Qiagen,) on an Mx3000P
QPCR system. Primers used for total TBX3 were: forward:
5′-CGC TGT GAC TGC ATA CCA GA-3′ and reverse:
5′-GTG TCC CGG AAA CCT TTT GC-3′. Primers used
for TBX3iso1 were: forward: 5′-AGT GGA TGT CCA
AAG TCG TCA C-3′ and reverse: 5′-CAT GGA GTT
CAA TAT AGT AAA TCC ATG TTT GTC TG-3′.
Primers used for TBX3iso2 were: forward: 5′-AGT GGA
TGT CCA AAG TCG TCA C-3′ and reverse: 5′-CAC
TTG GGA AGG CCA AAG TAA ATC CAT G-3′. Primers
used for GAPDH were: forward: 5′-AGG CTG GGG CTC
ATT TGC AG-3′ and reverse: 5-‘CCA TCC ACA GTC
TTC TGG GTG-3′. All primers were purchased from
Sigma-Aldrich. Output values were reported relative to
GAPDH as fold expression normalized to control cell lines.
Preparation of 21T cell lysates
Radioimmunoprecipitation (RIPA) buffer (10nM
Tris-HCl pH 7.5, 1 mM EDTA, 0.5 mM EGTA,
150nM NaCl, 1 % Triton-X 100, 0.5 % DOC, and
1 % SDS) containing one protease inhibitor tablet
per 10 ml (Complete, Mini, EDTA-free Protease In-
hibitor Cocktail, Roche) was used to lyse cells grown
as subconfluent monolayers in 10 cm dishes. The
cells were removed with a cell scraper, collected in a
clean microcentrifuge tube, and placed on a rotator
for 20 min at 4 °C. Tubes were spun at 13,000 RPM
for 10 min at 4 °C and the resulting supernatant was
collected.
Electrophoresis and Western blotting
Proteins were electrophoresed on 10 % polyacrylamide gels
and subsequently analyzed after transfer by Western blot
with mouse anti-TBX3 antibody (Abcam, ab58264;
1:2,000), anti-Vimentin (Dako, clone 3B4; 1:1,000), anti-
Twist (Abcam, ab50887; 1:1,000), anti-Src (Cell Signaling,
2108; 1:1,000), mouse anti-β-actin antibody (Abcam,
ab49900; 1:150,000), and anti-Vinculin (Sigma, V9264;
1:40,000). After incubation with the appropriate horseradish
peroxidase-conjugated secondary antibody (anti-mouse,
Amersham GE Healthcare; anti-rabbit, Sigma) diluted
1:10,000, protein bands were detected using ECL Plus
Western Blotting Detection Reagents (Amersham GE
Healthcare) and then exposed to film in a dark room.
Densitometric quantification was performed using ImageJ
(Open source software, National Institutes of Health, USA).
Immunohistochemistry of 21T cell pellets
Trypsinized cells were washed twice in phosphate
buffered saline (PBS), and pelleted in 15 ml conical
tubes. Pellets were re-suspended in 10 % neutral buff-
ered formalin (NBF) and stored at 4 °C overnight. For-
malin was removed, and pellets re-suspended in 1 ml
of 1 % agarose cooled to 35 °C. The hardened pellets
were wrapped in lens paper, cassetted, and processed
to paraffin. For histology, 4 μm sections were deparaf-
finized, pre-treated with 10 mM citrate buffer pH = 6
and blocked for endogenous peroxidises in 3 % H2O2/
methanol. Sections were immunostained with rabbit
anti-TBX3 antibody (Abcam, ab99302) diluted 1:300 at
4 °C overnight. Signal detection was accomplished
using ThermoScientific UltraVision LP Detection Sys-
tem (TL-060-HD).
Three-dimensional Matrigel culture and
immunofluorescence
Three-dimensional Matrigel culture was described previ-
ously [20–22]. Following a 9 day growth period, images
were taken at both 4X and 10X objective using an
inverted microscope. ImageJ (Open source software) was
used to determine colony formation rates by quantifying
the percentage of the population that formed colonies
greater than 50 μm in diameter. ImageJ was also used to
determine the proportion of circular colonies; a binary
quantification method was utilized, with a circular col-
ony having a circularity index above 0.75.
For immunofluorescence of Matrigel cultures, after
9 days of growth, the Matrigel plugs were fixed (10 %
NBF) and permeabilized (0.5 % Triton X-100 in PBS).
After blocking with normal goat serum (Invitrogen),
rabbit anti-Ki67 (Abcam, ab833) and anti-cleaved cas-
pase 3 (Cell Signaling, 9661) antibodies were incubated
at 1:150 dilution in 10 % normal goat serum overnight
at 4 °C. Cells were incubated with Alexa Fluor 488 Goat
Anti-Rabbit secondary antibody (Invitrogen, A11034)
and counterstained with Hoechst 33342 (Invitrogen,
H1399) and Alexa Fluor 546 Phalloidin (Invitrogen,
A22238). Coverslips were mounted over the stained
Matrigel plugs with ProLong Gold Antifade Reagent
(Invitrogen). Imaging was done using an Olympus Con-
focal Imaging System (FluoView FV1000 coupled to the
IX81 Motorized Inverted System Microscope). Nuclei
per colony were manually counted after acquiring 3D
colony images.
Transwell migration and invasion assays
To assess the migratory potential of 21NT cells overex-
pressing TBX3, transwell inserts with 8.0 μm pores (Corn-
ing, 3422; 24-well plate) were coated with a thin layer of
gelatin (6 μg) to serve as a substrate for migration without
obstructing movement through the pores. A 100 μl cell
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suspension (5 × 105 cells/ml in αHE with 0.1 % bovine
serum albumin (BSA)) was added to the upper chambers
and 0.75 ml αHE10F media was added to the bottom wells.
After incubation at 37 °C and 5 % CO2 for 22 h, migrated
cells were fixed with 1 % gluteraldehyde for 20 min and
stained with full-strength Hematoxylin for 15 min. Cells
that remained on top of the membrane were removed using
a cotton swab. Images of 5 non-overlapping fields of view
were acquired using Image-Pro Analysis Software (Media
Cybernetics) coupled to an inverted microscope at 10X ob-
jective. Cells were counted from the acquired images using
ImageJ (Open source software). Similarly, to assess the in-
vasive potential, transwell inserts with 8.0 μm pores pre-
coated with Matrigel (Corning, 354480) were used and
incubation lasted 22 h. Means derived from four replicates
were used during analysis.
RT2 PCR arrays
RNA was isolated from TBX3iso1 and TBX3iso2 trans-
fectants, as well as vector controls, using the RNeasy
Mini Kit (Qiagen). One microgram of RNA was con-
verted into cDNA using the RT2 First Strand Kit (Qia-
gen). RT2 SYBR Green Mastermix was combined with
the cDNA and dH2O as per the manufacturer’s proto-
col. Expression of 84 key genes commonly involved in
dysregulation of signal transduction pathways and other
biological processes involved in breast cancer were
assessed using Human Breast Cancer RT2 PCR arrays
(Qiagen, PAHS-131ZA-2). Data analysis was conducted
by SA Biosciences PCR Array Data Analysis Web portal
using the ΔΔCt method normalized to acidic ribosomal
phosphoprotein P0 (RPLP0) expression. Heat map
showing absolute expression of mRNA was generated
using the SA Biosciences RT2 profiler PCR Array Data
Analysis Web Portal.
Statistical analysis
Statistical analyses were done using GraphPad Prism
5.0 software (La Jolla, CA). Colony morphology experi-
ments, stain quantification, migration and invasion as-
says, and mRNA and protein levels were analyzed using
ANOVA followed by Tukey’s post hoc test (for com-
parison between more than two groups) or Student’s t-
test (for comparison between two groups). Proportions
were analyzed via Fisher’s exact test. For all analyses, p
< 0.05 was considered statistically significant.
Results
TBX3iso1 and TBX3iso2 are differentially expressed in the
21T cell lines
We have previously reported that TBX3 is present in
the 21T cell lines and that its expression is increased
in the 21MT-1 cell line representing IMC [7]. This
finding is consistent with previous reports that TBX3
is upregulated in invasive stages of cancer and led us
to examine TBX3 in detail using the 21T cell lines.
Expression levels of TBX3 mRNA and TBX3 protein
were examined in the parental 21T cell lines. Total
TBX3 expression was found to be higher in the inva-
sive 21MT-1 cells than in the non-invasive (21PT and
21NT) cell lines (Fig. 1a, d, e). Similarly, both
TBX3iso1 and TBX3iso2 were found to be expressed
at higher levels in 21MT-1 than in 21PT or 21NT
cells (Fig. 1b, c). In contrast, no difference in either
total TBX3 expression, or expression of either iso-
form, was seen between the ADH-like 21PT cells and
DCIS-like 21NT cells (Fig. 1a-e).
TBX3 expression is increased in 21NT (DCIS) cells after
stable transfection
In order to test the effect of TBX3 on breast cancer
progression, each TBX3 isoform was overexpressed in
the 21NT cell line (representing DCIS). TBX3 expres-
sion vectors for each isoform were constructed and
stably transfected into 21NT cells (21NT + TBX3iso1
and 21NT + TBX3iso2). An empty expression vector
containing the same antibiotic resistant gene (neo)
was also transfected into 21NT cells (21NT + EV).
qRT-PCR was used to determine the level of each
TBX3 isoform in transfected cells compared to empty
vector controls. Total TBX3 mRNA was increased (at
least 6-fold) in both 21NT + TBX3iso1 and 21NT +
TBX3iso2 transfectants (Fig. 2a) and the overexpres-
sion of TBX3 was isoform specific in the transfectants
(Fig. 2b, c). Likewise, Western blotting showed total
TBX3 protein was increased in both the 21NT +
TBX3iso1 cells and 21NT + TBX3iso2 cells, compared
to the empty vector control (Fig. 2d, e). Cell pellets of
TBX3 transfectants were assessed by immunohisto-
chemistry and TBX3 protein was found to be concen-
trated in the nucleus, remarkably more so in the TBX3
transfectants, consistent with TBX3’s known function
as a transcriptional regulator (Fig. 2f-g).
TBX3 overexpression promotes progression of 21NT
(DCIS) cells
To assess the role of TBX3 in the progression of DCIS to a
more malignant phenotype, the 3D morphology of the
21NT transfectants was assessed using a 3D Matrigel assay.
TBX3 overexpression greatly changed the phenotype of the
colonies in 3D Matrigel (Fig. 3a, b). TBX3 overexpression
increased the colony formation of the 21NT cells in a 3D
Matrigel system from 55 % for the empty vector controls to
66 % for the 21NT+TBX3iso1 cells and 63 % for the
21NT +TBX3iso2 cells (Fig. 3c). As an index of the infiltra-
tive vs. non-infiltrative nature of the colonies forming, we
used a circularity index to determine the proportion of col-
onies that were round (non-infiltrative). We found that
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TBX3iso1 and TBX3iso2 overexpression decreased the
proportion of round/circular colonies from 98 % for the
empty vector controls to 64 % for the 21NT +
TBX3iso1 cells and 64 % for the 21NT + TBX3iso2 cells
(Fig. 3d) (i.e. less rounded, more infiltrative colonies).
TBX3 overexpression also increased the number of nu-
clei per colony after 9 days from 34 nuclei per colony
for the empty vector control to 97 nuclei per colony for
the 21NT + TBX3iso1 cells and 89 nuclei per colony for
the 21NT + TBX3iso2 cells (Fig. 3e). Examination of
the colonies at day 9 by immunofluorescence for Ki67
and cleaved caspase 3 showed a significant increase in
Ki67 (Fig. 3f ) and decrease in cleaved caspase 3 (Fig. 3g)
expression for both TBX3iso1 and TBX3iso2 transfec-
tants vs. the negative control, resulting in an increase
in the proliferation to apoptosis (Ki67/cleaved caspase
3) ratio for both TBX3 transfectants (Fig. 3h).
To further assess the migratory and invasive ability of
TBX3-transfected 21NT cells, transwell assays were used.
21NT + EV, 21NT +TBX3iso1 and 21NT +TBX3iso2
cells were placed in the upper chamber of transwells
(membranes with 8.0 μm pores pre-coated with either a
thin layer of gelatin for migration assays, or Matrigel for
invasion assays) and allowed to invade through the pores
in order to reach 10 % FBS as an attractant in the lower
chamber. TBX3 (iso1 and iso2) overexpression increased
the 21NT cell’s ability to both migrate over gelatin (Fig. 4a,
b) and invade through Matrigel (Fig. 4c, d).
TBX3 knockdown reduces some characteristics of an
aggressive phenotype in 21MT-1 (IMC) cells
To examine whether reduction of TBX3 could have an ef-
fect at a later stage of progression, TBX3 was knocked
down in the 21MT-1 (IMC) cell line, using shRNA
Fig. 1 TBX3 isoform 1 and TBX3 isoform 2 are differentially expressed in the 21T cell lines. a Total TBX3 is differentially expressed in the 21T cell
lines. Primers for total TBX3 mRNA were used to detect total TBX3 levels in the 21T cell lines. TBX3 is significantly higher in the 21MT-1 cells compared to
the 21PT and 21NT cell lines and there is no significant difference in TBX3 expression between the 21PT and 21NT cells. b TBX3 isoform 1 is differentially
expressed in the 21T cell lines. Primers specific for TBX3iso1 were used to detect TBX3iso1 levels in the 21T cell lines. TBX3iso1 is significantly higher in the
21MT-1 cells compared to the 21PT and 21NT cell lines and there is no significant difference in TBX3iso1 expression between the 21PT and 21NT cells. c
TBX3 isoform 2 is differentially expressed in the 21T cell lines. Primers specific for TBX3iso2 were used to detect TBX3iso2 levels in the 21T cell lines.
TBX3iso2 is significantly higher in the 21MT-1 cells compared to the 21PT and 21NT cell lines and there is no significant difference in TBX3iso2 expression
between the 21PT and 21NT cells. d, e Total TBX3 protein is differentially expressed in the parental 21T cell lines. An antibody recognizing both isoforms of
TBX3 was used to assess the relative abundance of TBX3 within the 21T cell lines. Total TBX3 protein expression is significantly higher in the 21MT-1 cells
compared to the 21PT and 21NT cell lines and there is no significant difference in total TBX3 protein expression between the 21PT and 21NT cells. Means
were analyzed using one-way ANOVA followed by Tukey’s post hoc test and p< 0.05 was considered statistically significant; ** p< 0.01. Error bars indicate
Standard Error. Results are representative of at least three independent experiments
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targeting both isoforms. TBX3 expression in the knock-
down with the greatest reduction in both TBX3iso1 and
TBX3iso2 mRNA expression is compared to the off-target
(luciferase) control in Fig. 5a-c. qRT-PCR examination of
mRNA from this knockdown showed a five-fold reduction
in total TBX3 (Fig. 5a), TBX3iso1 (Fig. 5b), and TBX3iso2
(Fig. 5c). When examined at the level of protein expres-
sion by Western blotting (Fig. 5d, e), there was a
corresponding reduction in Tbx3 protein. While the
TBX3 knockdown cells were still able to form colonies at
a rate comparable with the luciferase control-transfected
cells in the 9-day Matrigel assay (Fig 5f, g), TBX3 knock-
down resulted in an increased proportion of round/circu-
lar colonies (i.e. less dispersed/infiltrative; Fig. 5h) and
fewer nuclei (cells) per colony (Fig. 5i), suggesting a reduc-
tion in invasiveness and impaired growth in 3D.
Fig. 2 TBX3 expression is increased in 21NT cell transfectants. a qRT-PCR with primer sets which recognize both isoforms of TBX3 show total
TBX3 mRNA is increased in 21NT cells after stable transfection with either TBX3iso1 or TBX3iso2. b qRT-PCR with TBX3iso1 specific primers show
TBX3iso1 mRNA is increased in 21NT cells after stable transfection with TBX3iso1. c qRT-PCR with TBX3iso2 specific primers show TBX3iso2 mRNA
is increased in 21NT cells after stable transfection with TBX3iso2. d Western blot showing total TBX3 protein is increased in the 21NT cells after
stable transfection with either TBX3iso1 or TBX3iso2. e Densitometry quantification of Western blot shows significantly higher TBX3 protein expression in
both the TBX3iso1 and TBX3iso2 transfectants. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test and p< 0.05 was considered
statistically significant; * p< 0.05, ***p< 0.001. Error bars indicate Standard Error. Results of the qRT-PCR and Western blot are representative of at least three
independent experiments. f Quantification of percentage of nuclei staining positive by immunohistochemistry for TBX3 in 21NT transfectant cell pellets. g
Immunohistochemistry for TBX3 in 21NT transfectant cell pellets. TBX3iso1 and TBX3iso2 vs. vector control show increased amount of protein, which is
mainly nuclear-localized
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Upregulation of TBX3 in 21NT (DCIS) cells results in
alterations in expression of key regulatory and EMT/
invasion associated genes
We used RT2 PCR arrays to profile mRNA expression of
TBX3iso1 and TBX3iso2 transfected 21NT cells, and found
a number of alterations in expression of key regulatory and
EMT/invasion-associated genes. As 21NT cells transfected
with either TBX3iso1 or TBX3iso2 had shown a similar
more aggressive phenotype, we focused our interest here
on those genes whose expression changed in common in
Fig. 3 TBX3 overexpression in DCIS-like 21NT cells results in a more aggressive phenotype in 3D Matrigel. TBX3 transfectants were seeded in 3D Matrigel
at 3000 cells per well and incubated at 37 °C and 5 % CO2 for 9 days. a Immunofluorescence images depicting colony size of 21NT transfectants. Cells were
grown in Matrigel for 9 days, then stained with Hoechst and Phalloidin and imaged using 60X objective. Scale bars represent 20 μm. b Brightfield and
phase contrast images showing growth of colonies after 9 days in 3D Matrigel. Brightfield images were taken using 4X objective, with
the scale bar representing 100 μm. Phase contrast images (inset) were taken using 40X objective, with the scale bar representing
20 μm. c TBX3 overexpression increases colony formation rates. A colony was considered to be successfully formed when larger than
50 μm in diameter. Analysis was conducted using ImageJ. d TBX3 overexpression decreased the proportion of round colonies. Analysis
was conducted using ImageJ. A binary quantification method was utilized; a circularity index above 0.75 was considered circular. e
TBX3 overexpression increases the number of nuclei per cell colony. f TBX3 overexpression resulted in an increase in the percentage
of Ki-67 positive cells within colonies. g TBX3 overexpression resulted in a decrease in the percentage of cleaved caspase 3 positive
cells within colonies. h The proliferation/apoptosis ratio, defined as the percentage of positive Ki67 cells divided by the percentage of
positive cleaved caspase three cells, increased with overexpression of both TBX3 isoforms. Means were analyzed using one-way ANOVA
followed by Tukey’s post hoc test. The proportion of circular colonies was analyzed using Fisher’s exact test. A value of p < 0.05 was
considered statistically significant; *p < 0.05, **p < 0.01, ***p < 0.001. Error bars indicate Standard Error. Results are representative of at
least three independent experiments
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both TBX3iso1- and TBX3iso2-transfected cells. We identi-
fied altered expression of a number of genes involved in sig-
nal transduction, cell cycle control/cell survival and EMT/
invasiveness (Fig. 6). In reference to pathways potentially
involved in control of cell cycle, proliferation vs. apoptosis
and cell survival, we observed significant down-regulation
of CDKN2A (previously shown to be a key gene directly
regulated by TBX3 in blocking cell senescence [12, 23]),
with upregulation of marker of proliferation Ki67 (MKI67);
Jun proto-oncogene (JUN); nuclear receptor subfamily 3,
group C, member 1 glucocorticoid receptor (NR3C1); epi-
dermal growth factor receptor (EGFR); androgen receptor
(AR); interleukin-6 (IL-6); SRC proto-oncogene (SRC); and
V-Akt murine thymoma viral oncogene homolog 1
(AKT1). Although the observed increase in retinoblastoma
1 (RB1), stratifin (SFN), breast cancer 1, early onset
(BRCA1) and breast cancer 2, early onset (BRCA2) may
seem counter-intuitive when the TBX3-upregulated cells
are found to be actively cycling and faster-growing, it is
likely that these are attempted adaptation responses to the
more direct (according to previous literature) effect of
CDKN2A down-regulation by TBX3, the expected result of
which would be release of cell-cycle checkpoint control, in-
hibition of senescence and apoptosis and promotion of pro-
gression through the cell cycle and cell proliferation.
Several genes potentially associated with EMT and cel-
lular invasiveness were also altered in transfectants of
both isoforms. Transcriptional regulators twist family
BHLH transcription factor 1 (TWIST1) and snail family
zinc finger 2 (SNAI2) were both upregulated, as was
SRC, and there was also altered expression of several
proteases and protease inhibitors (including upregula-
tion of plasminogen activator, urokinase (PLAU), serpin
peptidase inhibitor, clade E, member 1 (SERPINE1), and
Fig. 4 TBX3 overexpression increases migration and invasion of 21NT cells. a, b TBX3 overexpression increases migration using a transwell
migration assay. 21NT cell transfectants were placed in the upper chamber of a transwell migration system with media containing 1 % BSA and
allowed to migrate towards αHE10F chemoattractant in the bottom chamber for 22 h at 37 °C. Stable transfectants of both TBX3 isoforms
showed an increase in migration using the transwell system. Scale bars represent 100 μm. Results are quantified in panel (b). c, d TBX3
overexpression increases invasion using a transwell invasion system. 21NT cell transfectants were placed in the upper chamber of a transwell invasion
system with media containing 1 % BSA and allowed to invade towards αHE10F chemoattractant in the bottom chamber for 22 h at 37 °C. Stable
transfectants of both TBX3 isoforms showed an increase in invasion using the transwell system. Scale bars represent 100 μm. Results are quantified in
panel (d)
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Fig. 5 TBX3 knockdown results in a less aggressive phenotype of 21MT-1 (IMC) cells in 3D Matrigel. a Total TBX3 mRNA is decreased in 21MT-1 shTBX3
cells after TBX3 knockdown. b TBX3iso1 mRNA is significantly decreased in 21MT-1 shTBX3 after TBX3 knockdown. c TBX3iso2 mRNA is decreased in
21MT-1 after TBX3 knockdown. d Western blot showing total TBX3 protein is decreased in 21MT-1 shTBX3 cells after TBX3 knockdown. e Densitometry
quantification of Western blot shows that there is a significant decrease in TBX3 protein expression in the 21MT-1 shTBX3 cells. f Brightfield images
showing phenotype of colonies after 9 days in 3D Matrigel. Images were taken at 4X objective. Scale bars represent 100 μm. g, h, i Cells were seeded
in Matrigel and grown for 9 days. All of the cell lines were able to form colonies (g), but shTBX3 colonies were rounder (i.e. less dispersed, less invasive)
(h) and smaller (i). Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test. The proportion of circular colonies was analyzed
using Fisher’s exact test. A value of p < 0.05 was considered statistically significant; *p < 0.05, **p < 0.01, ***p < 0.001. Error bars indicate Standard Error.
Results are representative of at least 3 independent experiments
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Fig. 6 (See legend on next page.)
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matrix metallopeptidase 9 (MMP9); and downregulation
of cystatin E/M (CST6)). Up-regulation of mesenchymal
marker vimentin, as well as EMT-markers Twist and Src
were confirmed at the protein level as well (Fig. 6e).
Whether directly or indirectly, upregulation of either
isoform of TBX3 in 21NT cells thus induced alterations
in gene expression in pathways potentially involving cell
cycle/cell survival/cell growth control and EMT/inva-
siveness, with the resulting in vitro phenotypes of better
and larger colony formation, increased proliferation/
apoptosis ratio and increased motility and invasiveness
through Matrigel.
Discussion
By using the 21T cell line series to model the effects of pu-
tative drivers of the transition from pre-invasive to inva-
sive breast cancer progression, we are able to demonstrate
that overexpression of TBX3 can promote the transition
of DCIS to IMC. In particular, 21NT (DCIS-like) cells
overexpressing TBX3 (either iso1 or iso2) showed in-
creased colony-forming ability, with increased numbers of
cells per colony and a more dispersed (less “rounded”) col-
ony morphology. Increased cell invasiveness was also ob-
served, both in terms of more dispersed colonies in 3D
Matrigel and increased invasion through Matrigel in
transwells. In parallel, down-regulation of TBX3 in shRNA
transformants of 21MT-1 cells resulted in a less aggressive
phenotype in 3D Matrigel, with smaller and less dispersed
(less invasive) colony morphology.
No significant difference in functional activity in any
of these in vitro measures of malignancy was observed
between the two TBX3 isoforms. Interestingly, RT2 PCR
array analysis did show several differences in gene ex-
pression profiles induced by iso1 vs. iso2, as well as a
number of commonalities (Fig. 6a). As we saw no differ-
ence in functional effect, our analysis here was focused
on gene expression alterations occurring in common be-
tween the two isoforms, which could potentially explain
characteristics of the more aggressive phenotype seen in
both TBX3iso1 and TBX3iso2 transfectants.
Firstly, the increased colony-forming ability in 3D
Matrigel, with larger colony size and increased
proliferation vs. apoptosis ratio seen after transfection
of 21NT with both TBX3iso1 and TBX3iso2 indicated
an increased cell survival and predisposition for prolif-
eration vs. apoptosis (or senescence), effects that have
been previously ascribed to TBX3 in other systems
[10–12, 23]. Gene expression profiling of the TBX3
transfectants in our study showed altered expression
of several genes potentially involved in these processes
in both TBX3iso1 and TBX3iso2 transfected cells (i.e.
downregulation of CDKN2A (p14ARF, p16INK4A), with
upregulation of MKI67, JUN, NR3C1, EGFR, AR, IL-6,
SRC and AKT1). Perhaps most interesting of these is
the down regulation of CDKN2A (p14ARF, p16INK4A)
by both TBX3 isoforms, as previous studies have indi-
cated p14ARF in particular to be a direct transcrip-
tional target of TBX3 in other systems [23], and that
isolated down-regulation of p14ARF can accomplish
the same effect of increasing cell proliferation, de-
creasing cell senescence and apoptosis [12]. Further
work is required to determine whether p14ARF or
others of the candidate genes identified are respon-
sible for the cell survival/proliferation vs. apoptosis/
senescence aspects of the TBX3 phenotype in these
cells.
Another prominent aspect of the altered phenotype
seen with both TBX3iso1 and TBX3iso2 transfectants of
21NT cells was a more irregular/dispersed colony
morphology in 3D Matrigel, with increased cellular inva-
siveness in transwell assays, suggestive of an EMT effect.
In keeping with this, both TBX3iso1 and TBX3iso2
transfectants of 21NT cells showed alteration in expres-
sion of a number of EMT and invasion-related genes
that would be consistent with an EMT phenomenon, in-
cluding upregulation of TWIST1, SRC, SNAI2, PLAU,
SERPINE1, and MMP9, with downregulation of CST6.
Western blot analysis showed upregulation of Twist and
Src, along with mesenchymal marker Vimentin at the
protein level as well.
Our work is in agreement with that of previous studies
with other mammary epithelial cells (MCF-7, MDA-MB-
435, HC11) [24, 25] in which TBX3 was shown to have
functional effects including inhibition of senescence and
(See figure on previous page.)
Fig. 6 TBX3 overexpression in DCIS-like 21NT cells alters expression of key regulatory and EMT/invasion-associated genes. a Heat map (84 genes
commonly dysregulated in breast cancer) showing absolute mRNA expression of 84 breast-cancer related genes within the 21NT transfectant cells. b Fold
changes (mRNA) of genes significantly altered in expression in a similar fashion with overexpression of both TBX3iso1 and TBX3iso2 in 21NT cells. Data
analysis was conducted by SA Biosciences PCR Array Data Analysis Web portal using the ΔΔCt method normalized to acidic ribosomal phosphoprotein P0
(RPLP0) expression. Fold changes are compared to 21NT + EV control and are organized based on increasing fold change of TBX3iso1. The 24 genes shown
had similar alterations in gene expression with statistically significant fold changes for both isoforms (* p< 0.05, ** p< 0.01, ***p< 0.001). Genes in green
had reduced expression, and genes in red had increased expression at the mRNA level with TBX3 isoform overexpression. Results are representative of 3
RT2 PCR arrays per cell line. c Graphical representation of fold changes in panel (a). Dotted line represents normalized expression of transcript levels of
empty vector control cells (fold change = 1). d Gene expression changes with TBX3 isoform overexpression organized based on gene function groupings.
Genes in green had reduced expression, and genes in red had increased expression at the mRNA level with TBX3 isoform overexpression. e Western blot
showing increased expression of Vimentin, Twist and Src protein levels with TBX3 overexpression
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promotion of cell survival, proliferation and migration.
We present the added novel finding, using a progression
series of mammary epithelial cells, that overexpression
of TBX3 can trigger non-invasive (DCIS-like, 21NT)
cells to become invasive, possibly through an EMT-like
process. In addition, knockdown of TBX3 in invasive
(21MT-1) cells can revert them to a less aggressive
phenotype, with less potential for 3D growth and a less
infiltrative phenotype. Furthermore, we have shown that
these effects are not isoform specific, as both TBX3iso1
and TBX3iso2 were able to induce the same phenotypes
in transfected 21NT cells. Finally, examination of TBX3-
induced changes in gene expression of 21NT cells has
revealed specific cell survival/anti-senescence/prolifera-
tion and EMT/invasiveness category alterations, which
may be involved in the functional changes observed. Fu-
ture work will be necessary to establish which of these
changes may be key players in the TBX3-induced
phenotypes.
Conclusions
We have here demonstrated a role for both isoforms of
TBX3 (isoform 1 and 2) in promoting the transition
from non-invasive to invasive breast cancer. We have
shown that overexpression of TBX3 can alter cell prop-
erties involved in cell survival/colony formation and in-
vasiveness, as well as regulate EMT/invasiveness-related
genes. The identification of TBX3 as a potential regula-
tor of early breast cancer progression from DCIS to
IMC is of potential clinical utility not only in identifying
which DCIS lesions may be more likely to progress to
invasion, but along with a better understanding of the
role of specific TBX3-induced gene expression changes,
in providing other potential molecular targets to block
breast cancer progression at this early, pre-invasive
stage. The recent finding that TBX3 alterations may be
key driver mutations in breast cancer, and the suggestion
that altered (probably increased) TBX3 function may be
associated with at least some cases of familial breast can-
cer [26], adds particular significance to the potential of
TBX3 as an important regulator of breast cancer pro-
gression, and added urgency to a better understanding




This work was supported through the London Regional Cancer Program
Small Grants for Cancer Research and Training (ABT/AFC). MK, CDM, and LHS
each were the recipient of a Translational Breast Cancer Research
Studentship through the Pamela Greenaway-Kohlmeier Translational Breast
Cancer Research Unit (funded in part by the Breast Cancer Society of
Canada) and MK was also recipient of a CIHR Strategic Training Program in
Cancer Research and Technology Transfer award and Ontario Graduate
Scholarship. CDM was the recipient of an Alexander Graham Bell Canada
Graduate Scholarship and an Ontario Graduate Scholarship. HSL is the
recipient of Movember/PCC Rising Stars Awards. AFC is Canada Research
Chair in Oncology, supported by the Canada Research Chairs Program.
Availability of data and materials
All data generated during this study are included in this published article.
Authors’ contributions
MK, CDM, HSL, AFC, and ABT conceived and designed the experiments. MK,
CDM, HSL, AGC, LHS, DWD, and COP performed the experiments and
acquired the data. MK, CDM, HSL, AFC, and ABT interpreted the results. MK,
CDM, HSL, LHS, and ABT wrote the manuscript. All authors have read and
have approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Oncology, Schulich School of Medicine and Dentistry,
Western University, London, ON, Canada. 2The Pamela Greenaway-Kohlmeier
Translational Breast Cancer Research Unit, London Regional Cancer Program,
London Health Sciences Centre, London, ON, Canada. 3Department of
Pathology, Schulich School of Medicine and Dentistry, Western University,
London, ON, Canada. 4Department of Surgery, Schulich School of Medicine
and Dentistry, Western University, London, ON, Canada.
Received: 18 August 2015 Accepted: 9 August 2016
References
1. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of
the female breast. A long-term follow-up study. Cancer. 1985;55(11):2698–
708. doi:10.1097/00006534-198604000-00059.
2. Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of
increased breast cancer risk. Breast Cancer Res Treat. 1993;28(2):157–66. doi:
10.1007/BF00666428.
3. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of
the breast: clonal proliferation with loss of heterozygosity on chromosomes
16q and 17p. J Clin Pathol. 1995;48(7):611–5. doi:10.1136/jcp.48.7.611.
4. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of
human premalignant breast disease. Endocr Relat Cancer. 2001;8(1):47–61.
doi:10.1677/erc.0.0080047.
5. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma
in situ and the emergence of diversity during breast cancer evolution. Clin
Cancer Res. 2008;14(2):370–8. doi:10.1158/1078-0432.CCR-07-1127.
6. Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease:
biology and clinical implications. Ann Intern Med. 2005;143(6):446–57. doi:
10.7326/0003-4819-143-6-200509200-00009.
7. Souter LH, Andrews JD, Zhang G, Cook AC, Postenka CO, Al-Katib W, et al.
Human 21T breast epithelial cell lines mimic breast cancer progression in
vivo and in vitro and show stage-specific gene expression patterns. Lab
Invest. 2010;90(8):1247–58. doi:10.1038/labinvest.2010.97.
8. Eblaghie MC, Song SJ, Kim JY, Akita K, Tickle C, Jung HS. Interactions between
FGF and Wnt signals and Tbx3 gene expression in mammary gland initiation in
mouse embryos. J Anat. 2004;205(1):1–13. doi:10.1111/j.0021-8782.2004.00309.x.
9. Bamshad M, Le T, Watkins WS, Dixon ME, Kramer BE, Roeder AD, et al. The
spectrum of mutations in TBX3: Genotype/Phenotype relationship in ulnar-
mammary syndrome. Am J Hum Genet. 1999;64(6):1550–62. doi:10.1086/302417.
10. Brummelkamp TR, Kortlever RM, Lingbeek M, Trettel F, MacDonald ME, van
Lohuizen M, et al. TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is
a negative regulator of p19ARF and inhibits senescence. J Biol Chem. 2002;
277(8):6567–72. doi:10.1074/jbc.M110492200.
11. Carlson H, Ota S, Song Y, Chen Y, Hurlin PJ. Tbx3 impinges on the p53 pathway
to suppress apoptosis, facilitate cell transformation and block myogenic
differentiation. Oncogene. 2002;21(24):3827–35. doi:10.1038/sj.onc.1205476.
Krstic et al. BMC Cancer  (2016) 16:671 Page 13 of 14
12. Rowley M, Grothey E, Couch FJ. The role of Tbx2 and Tbx3 in mammary
development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2004;
9(2):109–18. doi:10.1023/B:JOMG.0000037156.64331.3f.
13. Rodriguez M, Aladowicz E, Lanfrancone L, Goding CR. Tbx3 represses E-
cadherin expression and enhances melanoma invasiveness. Cancer Res.
2008;68(19):7872–81. doi:10.1158/0008-5472.CAN-08-0301.
14. Boyd SC, Mijatov B, Pupo GM, Tran SL, Gowrishankar K, Shaw HM, et al.
Oncogenic B-RAF(V600E) signaling induces the T-Box3 transcriptional
repressor to repress E-cadherin and enhance melanoma cell invasion. J
Invest Dermatol. 2013;133(5):1269–77. doi:10.1038/jid.2012.421.
15. Renard CA, Labalette C, Armengol C, Cougot D, Wei Y, Cairo S, et al. Tbx3 is
a downstream target of the Wnt/beta-catenin pathway and a critical
mediator of beta-catenin survival functions in liver cancer. Cancer Res. 2007;
67(3):901–10. doi:10.1158/0008-5472.CAN-06-2344.
16. Fan W, Huang X, Chen C, Gray J, Huang T. TBX3 and its isoform TBX3 + 2a
are functionally distinctive in inhibition of senescence and are
overexpressed in a subset of breast cancer cell lines. Cancer Res. 2004;
64(15):5132–9. doi:10.1158/0008-5472.CAN-04-0615.
17. Hoogaars WM, Barnett P, Rodriguez M, Clout DE, Moorman AF, Goding CR,
et al. TBX3 and its splice variant TBX3 + exon 2a are functionally similar.
Pigment Cell Melanoma Res. 2008;21(3):379–87. doi:10.1111/j.1755-148X.
2008.00461.x.
18. Band V, Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, et al. Tumor
progression in four mammary epithelial cell lines derived from the same
patient. Cancer Res. 1990;50(22):7351–7.
19. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, et al. A
lentiviral RNAi library for human and mouse genes applied to an arrayed viral
high-content screen. Cell. 2006;124(6):1283–98. doi:10.1016/j.cell.2006.01.040.
20. MacMillan CD, Leong HS, Dales DW, Robertson AE, Lewis JD, Chambers AF,
et al. Stage of breast cancer progression influences cellular response to
activation of the WNT/planar cell polarity pathway. Sci Rep. 2014;4:6315. doi:
10.1038/srep06315.
21. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of
MCF-10A mammary epithelial acini grown in three-dimensional basement
membrane cultures. Methods. 2003;30(3):256–68. doi:10.1016/S1046-
2023(03)00032-X.
22. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of
normal and malignant breast epithelial cells. Nat Methods. 2007;4(4):359–65.
doi:10.1038/nmeth1015.
23. Yarosh W, Barrientos T, Esmailpour T, Lin L, Carpenter PM, Osann K, et al.
TBX3 is overexpressed in breast cancer and represses p14 ARF by
interacting with histone deacetylases. Cancer Res. 2008;68(3):693–9. doi:10.
1158/0008-5472.CAN-07-5012.
24. Peres J, Davis E, Mowla S, Bennett DC, Li JA, Wansleben S, et al. The Highly
Homologous T-Box Transcription Factors, TBX2 and TBX3, Have Distinct
Roles in the Oncogenic Process. Genes Cancer. 2010;1(3):272–82. doi:10.
1177/1947601910365160.
25. Platonova N, Scotti M, Babich P, Bertoli G, Mento E, Meneghini V, et al. TBX3,
the gene mutated in ulnar-mammary syndrome, promotes growth of
mammary epithelial cells via repression of p19ARF, independently of p53.
Cell Tissue Res. 2007;328(2):301–16. doi:10.1007/s00441-006-0364-4.
26. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al.
The landscape of cancer genes and mutational processes in breast cancer.
Nature. 2012;486(7403):400–4. doi:10.1038/nature11017.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Krstic et al. BMC Cancer  (2016) 16:671 Page 14 of 14
